Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: A randomised trial

Tuesday, January 25th, 2022

This was a prospective, randomized, open-label, crossover study that compared inhaled mannitol with recombinant human deoxyribonuclease in 38 children with cystic fibrosis. The primary endpoint was FEV1; secondary endpoints were FVC, FEF25–75, pulmonary exacerbations, sputum microbiology, exercise tolerance, QoL and adverse events. Pulmonary function endpoints were measured using a Vitalograph COMPACT spirometer, which was calibrated with a 1L syringe before each visit.